Diabetes Mellitus, Type 2 Clinical Trial
— DOORSOfficial title:
A Multicentre, Prospective, Non-Interventional, Single-Arm Study Investigating Glycaemic Control and Patient-Reported Outcomes in Type 2 Diabetes Patients, Uncontrolled on DPP4i Treatment and Who Switch to Oral Semaglutide in a Real-World Setting in Italy
Verified date | May 2024 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who change their treatment from DPP4i to oral semaglutide. Participant will get oral semaglutide as prescribed by the study doctor. The study will last for about 5-6 months. Participants will be asked to complete two questionnaires. One will be about eating behaviour and the other one will be diabetes related. Participant will complete this questionnaire during the normal scheduled visit with study doctor. Participants will be asked questions about their health and diabetes treatment and lab tests as part of their normal doctor's appointment.
Status | Active, not recruiting |
Enrollment | 390 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) - The decision to switch from DPP4i treatment to commercially available oral semaglutide has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study - Participant with last measurement of HbA1c >= 7.5% at informed consent and treatment initiation visit (V1) or less than or equal to (<=) 90 days before informed consent and treatment initiation visit (V1) - Treatment naïve to insulin. An exception is short-term insulin treatment for acute illness for a total of < 14 days Exclusion Criteria: - Previous participation in this study. Participation is defined as having given informed consent in this study - Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to the informed consent and treatment initiation visit (V1) and throughout the duration of the study - Participants with type-1 diabetes - Participants who are pregnant or who become pregnant (or who plan to become pregnant) during the study period - Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. - Age < 18 years on the informed consent and treatment initiation visit (V1) |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale Pesenti Fenaroli | Alzano Lombardo | |
Italy | INRCA | Ancona | |
Italy | A.O.U. Policlinico S.Orsola | Bologna | |
Italy | Ospedale centrale L. Bohler | Bolzano | |
Italy | ASL Caserta | Caserta | |
Italy | Azienda Ospedaliera Cannizzaro | Catania | |
Italy | ASL Cuneo 1 | Cuneo | |
Italy | Università degli Studi Foggia | Foggia | |
Italy | Ospedale Misericordia | Grosseto | |
Italy | Ospedale Generale provinciale | Macerata | |
Italy | Ospedale Pagliari | Massafra | |
Italy | ASL Avellino | Montoro | |
Italy | ASL Lecce | Nardò | |
Italy | ASL Napoli 3 sud | Palma Campania | |
Italy | A.O.U. Maggiore della Carità | Piemonte | |
Italy | Ospedale San Jacopo | Pistoia | |
Italy | P.O. Praia a Mare | Praia a Mare | |
Italy | Casa della Salute ASL RM2 | Roma | |
Italy | Fondazione Univ. Policlinico A.Gemelli | Roma | |
Italy | Ospedale Santo Spirito | Roma | |
Italy | A.O.U. Policlinico Giaccone | Sicilia | |
Italy | Casa di cure Triolo Zancla | Sicilia | |
Italy | Ospedale Treviglio | Treviglio | |
Italy | Ospedale S. Maria della Misericordia | Udine | |
Italy | ASST Sette Laghi | Varese |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absolute change in glycated haemoglobin (HbA1c) (percentage [%]-point) | Measured in %-point. | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Primary | Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]) | Measured in mmol/mol. | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Relative change in body weight | Measured in percentage (%). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Absolute change in body weight | Measured in Kilograms (kg). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Absolute change in lipid parameters (total cholesterol, low density lipoprotein cholesterol [LDLc], high density lipoprotein cholesterol [HDLc], triglycerides) | Measured in millimoles per liter (mmol/L). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Absolute change in waist circumference | Measured in centimeters (cm). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Absolute change in blood pressure (systolic and diastolic) | Measured in millimeters of mercury (mmHg). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Number of participants with HbA1c less than (<) 7% | Measured as number of participants (yes or no). | At end of study (week 40 ± 4 weeks) | |
Secondary | Number of participants with HbA1c <6.5% | Measured as number of participants (yes or no). | At end of study (week 40 ± 4 weeks) | |
Secondary | HbA1c reduction greater than or equal to (>=) 1%-point and body weight reduction of >= 5% | Measured as number of participants (yes or no). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | HbA1c reduction greater than or equal to (>=) 1%-point and body weight reduction of >= 3% | Measured as number of participants (yes or no). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Self-reported severe hypoglycaemia during the study period | Measured as number of participants (yes or no). | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Absolute change in dutch eating behaviour questionnaire (DEBQ) scores (points) | DEBQ is a 33-item self-reported questionnaire to assess three distinct eating behaviours in adults: emotional eating, external eating, and restrained eating. For all 33 items participants will provide response in terms of: never, seldom, sometimes, often, very often. Absolute change in DEBQ (total score) calculated as the absolute difference between the DEBQ scores (total score) at baseline and post baseline measurements of DEBQ scores (total score) up to and including end of study visit. | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) | |
Secondary | Absolute change in diabetes distress survey (DDS) scores (points) | DDS is a self-administered 17-item scale that captures four critical dimensions of diabetes-related distress: emotional burden, regimen distress, interpersonal distress, and physician distress. Each item was scored in the range of 1 to 6: 1) not a problem; 2) a slight problem; 3) a moderate problem; 4) somewhat serious problem; 5) a serious problem; 6) a very serious problem. Participants will rate each item item indicating the degree to which each of the 17 items may have distressed or bothered them during the past month. High score indicated high distress. | From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |